相关实验视频

Updated: May 15, 2025

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

评估尼卡迪平延长释放植入物的有效性在患有下大脑关节出血的患者:一个元分析和元回归分析

Ibrahim Khalil¹, Imran Hossain², Arindam Das Joy¹

¹Dhaka Medical College and Hospital, Dhaka, Bangladesh.

Annals of medicine and surgery (2012)

|April 11, 2025

概括

尼卡迪植入物显著降低脑血管和延迟脑缺血症 (DCI) 在下关节出血 (SAH) 患者. 然而,这些植入物没有改善功能结果,这表明需要额外的康复策略.

科学领域:

神经外科神经外科
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

副arachnoid出血 (SAH) 具有重大风险,包括大脑血管和延迟大脑缺血 (DCI),导致高发病率和死亡率.
尼卡迪平是一种通道阻塞剂,正在研究其减轻SAH相关并发症的潜力.

研究的目的:

评估尼卡迪平延长释放植入物的疗效和安全性,用于管理下大脑关节出血并发症.
评估尼卡迪平植入物对大脑血管,DCI和SAH患者的功能结果的影响.

主要方法:

对7项研究 (775名患者) 进行了元分析,包括随机对照试验和观察性研究.
文献搜索包括PubMed,科克伦图书馆,Embase和临床试验.gov.gov.
主要结局:大脑血管的发生率. 二级结局:DCI,延迟缺血性神经缺陷 (DIND) 和功能结局 (修改的兰金级).

主要成果:

尼卡迪植入物显著降低了脑血管 (RR=0.38,P<0.0001) 和DCI (RR=0.33,P=0.0002) 的风险.
没有观察到对DIND (RR=0.68,P=0.29) 或功能结果 (RR=2.03,P=0.11) 的显著影响.

结论:

尼卡迪延长释放植入物在SAH后减少大脑血管和DCI方面表现出有效性.
植入物没有显著改善功能结果,强调了补充康复的必要性.
需要进一步的大规模研究来验证这些发现.

关键词:

大脑血管是什么意思延迟大脑缺血症的发生进行元分析分析.尼卡迪平的植入物可以植入内脏.脑下关节下部出血

更多相关视频

Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model

Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model

Published on: June 18, 2021

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

相关概念视频

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...